Healthcare costs associated with varicella and herpes zoster in Norway |
| |
| Affiliation: | 1. Investigator site, Piazza Ponchielli 1, Toscana, Grosseto, GR 58100, Italy;2. Investigator site, Via Terranova 2, Puglia, Parabita, LE 73052, Italy;3. Investigator site, Via B. di Fredi 24, Toscana, Civitella Paganico, GR 58045, Italy;4. Investigator site, Via Garibaldi 1, Piemonte, Frugarolo, AL 15065, Italy;5. Investigator site, Via Vittorio Veneto 44/A, Lombardia, Sesto Calende, VA 21018, Italy;6. Investigator site, Viale della Repubblica snc, Puglia, Cutrofiano, LE 73020, Italy;7. Investigator site, Via Cavour 26, Lombardia, Arcisate, VA, 21051, Italy;8. Investigator site, Via Cechov 3/Q, Lazio, Roma, RM 00142, Italy;9. Investigator site, Via Pietro Tacchini 7, Lazio, Roma, RM 00197, Italy;10. Investigator site, Central Site, Società Italiana di Medicina Generale (SIMG), Via del Pignoncino 9 SIMG, Toscana, Firenze, FI 50142, Italy;11. GSK, Via Fleming 2, Veneto, Verona, VR 37135, Italy;12. GSK, Embassy Links, Cunningham Road, SRT Road, #5, Bangalore 560052, India;13. GSK, Stockley park, Iron Bridge Rd N, UB11 1BT, United Kingdom;1. GSK, Wavre, Belgium;2. Freelance c/o GSK, Wavre, Belgium;3. Hackensack University Medical Center, Hackensack, New Jersey;4. University of Minnesota, Minneapolis, Minnesota;5. Haematology Department, G. Papanikolaou General Hospital of Thessaloniki, Thessaloniki, Greece;6. Hacettepe University Medical Faculty, Ankara, Turkey;7. Karmanos Cancer Center, Wayne State University, Detroit, Michigan;8. Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia;9. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;10. GSK, Rixensart, Belgium;11. Hospital General Universitario J. M. Morales Meseguer, Murcia, Spain;12. Department of Haematology, St Vincent''s Hospital, Darlinghurst, New South Wales, Australia;13. Hospital Virgen de la Arrixaca, Murcia (El Palmar), Spain;14. Hospital Puerta de Hierro, Majadahonda (Madrid), Spain;15. Department of Haematology, Jagiellonian University Medical College, Cracow, Poland;16. Complejo Hospitalario Dr. Arnulfo Arias Madrid, Panama, Panama;17. Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada;18. Department of Hematology and Oncology, Charité University Medical Center, Berlin, Germany;19. Hematologie, AZ Sint-Jan Brugge-Oostende AV–Campus Sint-Jan, Brugge, Belgium;20. Duke University Medical Center, Durham, North Carolina;21. Jessa Ziekenhuis–Campus Virga Jesse, Hasselt, Belgium;22. Gazi University Medical Faculty, Ankara, Turkey;23. Department of Hematology, China Medical University Hospital, Taichung, Taiwan;24. Clinica Ematologica, Azienda Ospedaliero Universitaria S. Maria Misericordia, Friuli-Venezia-Giulia, Udine, Italy;25. Royal Melbourne Hospital, Melbourne, Victoria, Australia |
| |
| Abstract: | BackgroundNorway does not implement routine vaccination against varicella or herpes zoster. Despite substantial health burden associated with both diseases, their economic impact is not well described. The aim of the present study was to document the healthcare costs associated with both conditions in a Norwegian setting.MethodsWe used registry data about patients’ contacts with primary and specialized healthcare services from 2008 to 2014 to estimate the costs associated with varicella and herpes zoster in the primary and hospital care sector. We calculated the individual costs by treatment facility (general practitioner and emergency primary care clinic) in primary care and by treatment level (inpatient, outpatient or ambulatory treatment) at hospitals.ResultsWe estimate that the annual healthcare cost of patients with varicella and herpes zoster are NOK 85 million (approximately € 9 million). Of the annual costs, 73% are associated with herpes zoster and 27% are due to varicella. The majority (54%) of the total annual cost is represented by patients with herpes zoster treated in hospital.ConclusionVaricella and herpes zoster impose a substantial financial burden on the national healthcare services in Norway. Most of the costs are incurred by herpes zoster, which could be prevented by vaccination. |
| |
| Keywords: | Cost of illness Varicella Herpes zoster |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
